Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience

Table 1 Baseline characteristics

Patient No.	Age (yr)	Sex	PLA2R	Duration (mo)	Previous treatment	Effect	Side effect	Current treatment
1	57	M	+	12	(1) RTX 500 mg iv twice in two months; and (2) Pre 40 mg/d + CSA 150 mg/d	SR	Serum glucose up	Pre + TAC
2	28	M	+	54	(1) Pre 20 mg/d + TAC 2 mg/d; and (2) Pre 24 mg/d + TAC 2 mg/d	SR	Cushing’s syndrome	Pre + TAC
3	40	M	+	21	(1) CSA 150 mg/d; (2) Pre 20 mg/d + CTX 100 mg/d; and (3) Pre 30 mg + TAC 2 mg/d	SR	Hypertension	Pre + TAC
4	60	F	+	51	(1) TAC 2 mg/d; and (2) Pre 20 mg + CSA 150 mg/d	SR	Steroid-induced diabetes	Non
5	31	M	+	9	(1) CsA 150 mg/d; (2) Pre 48 mg/d + TAC 2 mg/d; and (3) Pre 48 mg/d + CTX 100 mg/d	SD	Steroid-induced diabetes; liver damage; Hypertension	Pre + TAC
6	29	F	+	31	(1) Pre 15 mg/d + CSA 150 mg/d; (2) Pre 40 mg/d + LEF 30 mg/d; and (3) Pre 25 mg/d + TAC 2 mg/d	SD	Cushing’s syndrome; Hypertension	Pre
7	49	M	+	44	(1) Pre 40 mg/d + CSA 150 mg/d; and (2) Pre 24 mg/d + TAC 2 mg/d	SD	Cushing’s syndrome; Steroid-induced diabetes	Pre + TAC
8	49	F	+	35	(1) Pre 50 mg/d + CTX 1000 mg iv; (2) Pre 30 mg/d + CSA 150 mg/d; and (3) TAC 3 mg/d	SR	Cushing’s syndrome; Liver damage; Steroid-induced diabetes	Non
9	36	F	+	18	(1) Pre 24 mg/d + CSA 100 mg/d; and (2) TAC 2 mg/d	SR	Non	Non

M: Male; F: Femle; PLA2R: Phospholipase A2 receptor; RTX: Rituximab; Pre: Prednisone; CAS: Cyclosporine; TAC: Tacrolimus; LEF: Leflunomide; SR: Steroid-resistant; SD: Steroid-dependent.